Cargando…
Co-targeting BCL-X(L) and MCL-1 with DT2216 and AZD8055 synergistically inhibit small-cell lung cancer growth without causing on-target toxicities in mice
Small-cell lung cancer (SCLC) is an aggressive malignancy with limited therapeutic options. The dismal prognosis in SCLC is in part associated with an upregulation of BCL-2 family anti-apoptotic proteins, including BCL-X(L) and MCL-1. Unfortunately, the currently available inhibitors of BCL-2 family...
Autores principales: | Khan, Sajid, Kellish, Patrick, Connis, Nick, Thummuri, Dinesh, Wiegand, Janet, Zhang, Peiyi, Zhang, Xuan, Budamagunta, Vivekananda, Hua, Nan, Yang, Yang, De, Umasankar, Jin, Lingtao, Zhang, Weizhou, Zheng, Guangrong, Hromas, Robert, Hann, Christine, Zajac-Kaye, Maria, Kaye, Frederic J., Zhou, Daohong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9806104/ https://www.ncbi.nlm.nih.gov/pubmed/36588105 http://dx.doi.org/10.1038/s41420-022-01296-8 |
Ejemplares similares
-
BCL-X(L) PROTAC degrader DT2216 synergizes with sotorasib in preclinical models of KRAS(G12C)-mutated cancers
por: Khan, Sajid, et al.
Publicado: (2022) -
Overcoming Gemcitabine Resistance in Pancreatic Cancer Using the BCL-X(L)–Specific Degrader DT2216
por: Thummuri, Dinesh, et al.
Publicado: (2022) -
DT2216—a Bcl-xL-specific degrader is highly active against Bcl-xL-dependent T cell lymphomas
por: He, Yonghan, et al.
Publicado: (2020) -
Safety, tolerability, pharmacokinetics and pharmacodynamics of AZD8055 in advanced solid tumours and lymphoma
por: Naing, A, et al.
Publicado: (2012) -
BCLXL PROTAC degrader DT2216 targets secondary plasma cell leukemia addicted to BCLXL for survival
por: Champion, Ophélie, et al.
Publicado: (2023)